Biology, data, and the industry it built
Incretins are bigger than GLP-1
GLP-1 made the headlines. Explore the two established human incretins, the adjacent peptide systems now combined with them, and evidence spanning cardiovascular, kidney, liver, neurologic, and addiction medicine.
+ aging
Interactive explorer
Incretins
across disease
Filter by outcome. Incretin receptor agonists are approved, in Phase 3, or have failed outright across seven distinct disease categories. Click a card to open the primary source.
The most interesting open question
The GIP
paradox
Two drugs do opposite things to the same receptor. Both cause major weight loss. Here is the leading explanation.
Beyond the two incretins
The peptide
network
GLP-1 and GIP are the two established human incretins. Modern drug programs also combine or compare them with related gut and pancreatic peptide systems.
| Hormone | Source gene | Physiological role | Drug examples | Status |
|---|
The next wave
Next-generation
pipeline
Dual and triple agonists, amylin combinations, and oral small molecules pushing past single-target GLP-1.
| Candidate | Company | Targets | Phase | Weight loss | Dosing |
|---|
An interactive history